drugset
drugset / Trial / NCT01617668

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer

NCT01617668 ↗

Phase 2 Completed 209 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression

Timeline

Start
2012-08
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LCL161 Small molecule 1800 mg Oral
Background Paclitaxel Small molecule 80 mg/m2 Intravenous

Indications

breast cancer